<!DOCTYPE html>
<html lang="en">
<head>
<title>Hepatitis A</title>
<meta http-equiv="Content-Type" content="text/html;charset=utf-8">
<link rel="stylesheet" type="text/css" href="../../../public/css/offline.css" />
<script src="../../../public/javascripts/jquery-1.10.2.min.js"></script>
</head>
<body class="dsg-wb">

<table width="80%" class="offline">
<tr>
  <td colspan="3" class="header"><h1><a href="/">JPAC</a> <span>Joint United Kingdom (UK) Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee</span></h1></td>
</tr>
<tr class="tabs">
  <td colspan="3">
              <ul>
                  <li id="64df60ce-a8e2-4c07-8729-68f41eb42fc3" class="whole-blood-and-components"><a href="../../../dsg/wb/guidelines.html"  class="active">Whole Blood and Components</a></li>
                  <li id="ddb09bf2-3dc0-4eb2-ba57-a5db69331dd1" class="geographical-disease-risk-index"><a href="../../../dsg/gdri/guidelines.html" >Geographical Disease Risk Index</a></li>
                </ul>
        </td>
</tr>
<tr>
  <td class="spacerow" colspan="3"></td>
</tr>
<tr>
  <td class="sidebar" width="25%">
    <div class="well">
          <ul class="openContentSectionWithSubs sidebarTopHeader"><li id="64df60ce-a8e2-4c07-8729-68f41eb42fc3" class="whole-blood-and-components sectionHead first last"><a href="../../../dsg/wb.html">Whole Blood and Components</a>
<ul class="">
<li id="42be2de8-89aa-4908-8bc8-702f9e636a81" class="a-z-search active first"><a href="../../../dsg/wb/guidelines.html">A-Z Search</a>
</li><li id="1f7e1f13-8b29-4772-ae9d-2b5cc3d59491" class="updates"><a href="../../../dsg/wb/latest-updates.html">Updates</a>
</li><li id="f83d68fb-19de-4588-9a36-a8bba0aa6494" class="drug-index"><a href="../../../dsg/wb/drug-index.html">Drug Index</a>

</li><li id="769da873-1c35-4600-8be8-d2df902570a0" class="preliminaries"><a href="../../../dsg/wb/preliminaries.html">Preliminaries</a>
<ul class="">
<li id="258895c3-f3dd-45c6-932c-3fe4795870c2" class="introduction first"><a href="../../../dsg/wb/preliminaries/introduction.html">Introduction</a>
</li><li id="ef298454-8327-4f6c-9f4a-835e437df103" class="document-and-change-control"><a href="../../../dsg/wb/preliminaries/document-and-change-control.html">Document and Change Control</a>
</li><li id="093e6463-a089-49dd-9199-c8f92559f486" class="general-principles"><a href="../../../dsg/wb/preliminaries/general-principles.html">General Principles</a>
</li><li id="96f75c3a-2c62-445b-847c-353098eaec1e" class="medication"><a href="../../../dsg/wb/preliminaries/medication.html">Medication</a>
</li><li id="ed51942d-a7fd-42f7-8269-d23b879f99ca" class="inspection-of-the-donor"><a href="../../../dsg/wb/preliminaries/inspection-of-the-donor.html">Inspection of the Donor</a>
</li><li id="99af8b5e-491b-4d67-b69a-812d81af4d7d" class="use-of-alphabetical-listing last"><a href="../../../dsg/wb/preliminaries/use-of-alphabetical-listing.html">Use of Alphabetical Listing</a>
</li></ul>
</li><li id="753eb36f-2636-414c-84ee-1004e197502d" class="appendices"><a href="../../../dsg/wb/appendicies.html">Appendices</a>
<ul class="">
<li id="e147bd96-a025-4ffa-b530-b9abefc27043" class="appendix-1---estimated-blood-volume-for-female-donors-after-nadler--by-height-and-weight first"><a href="../../../dsg/wb/appendicies/appendix-1.html">Appendix 1 - Estimated Blood Volume for Female donors (after Nadler)  by height and weight</a>
</li><li id="2f1eca54-e34f-4ece-90a4-7dfe0f210c8d" class="appendix-2---table-of-immunisations-"><a href="../../../dsg/wb/appendicies/appendix-2-table-of-immunizations.html">Appendix 2 - Table of Immunisations </a>
</li><li id="a27f8ce9-b4f6-4a9b-baf0-6f655955a9aa" class="appendix-3---maximum-permitted-ecv-for-component-donors"><a href="../../../dsg/wb/appendicies/appendix-3-maximum-permitted-extra-corporeal-volume-for-component-donors.html">Appendix 3 - Maximum permitted ECV for component donors</a>
</li><li id="90c869cb-7256-4604-8699-d8a86f78aa26" class="appendix-4---management-of-post-donation-illness last"><a href="../../../dsg/wb/appendicies/appendix-4-management-of-post-donation-illness.html">Appendix 4 - Management of post donation illness</a>
</li></ul>
</li><li id="b62a2d12-6d94-4106-92a8-1de426a4b863" class="source-files last"><a href="../../../dsg/wb/source-files.html">Source Files</a>
</li></ul>
</li></ul>
    </div>
  </td>
  <td width="5%"></td>
  <td width="70%" class="content">
    <h2>Hepatitis A</h2>    

<table class="data-table"><tbody><tr><td class="data-sub" colspan="2"><table class="data-sub-table"><tbody><tr><td class="data-header" colspan="2">1. Affected Individual</td></tr><tr class="data-row"><td class="data-label">Obligatory</td><td class="data-value"><p><b>Must not donate if:</b></p>


<ul>
	<li>less than 6 months from recovery of symptoms, and</li>
	<li>less than 6 months since the donor was diagnosed with hepatitis A infection following laboratory testing.</li>
</ul></td></tr><tr class="data-row"><td class="data-label">See if Relevant</td><td class="data-value"><p><a href="../../../dsg/wb/guidelines/tr005-travel.html">Travel</a></p></td></tr></tbody></table></td></tr><tr><td class="data-sub" colspan="2"><table class="data-sub-table"><tbody><tr><td class="data-header" colspan="2">2. Current or Former Sexual Partner of Affected Individual</td></tr><tr class="data-row"><td class="data-label">Obligatory</td><td class="data-value"><p><b>Must not donate if less than 6 months:</b></p>


<ul>
	<li>since a current sexual partner has recovered from symptoms of hepatitis A, or</li>
	<li>since a current sexual partner tested positive for hepatitis A RNA, or</li>
	<li>since last sexual contact with a former sexual partner who had hepatitis A.</li>
</ul></td></tr></tbody></table></td></tr><tr><td class="data-sub" colspan="2"><table class="data-sub-table"><tbody><tr><td class="data-header" colspan="2">3. Person Currently or Formerly Sharing a Home with an Affected Individual</td></tr><tr class="data-row"><td class="data-label">Obligatory</td><td class="data-value"><p><b>Must not donate if less than 6 months:</b></p>


<ul>
	<li>from recovery of the last affected person in the home, or</li>
	<li>since a person sharing a home tested positive for hepatitis A RNA.</li>
</ul></td></tr></tbody></table></td></tr><tr><td class="data-sub" colspan="2"><table class="data-sub-table"><tbody><tr><td class="data-header" colspan="2">4. Immunisation</td></tr><tr class="data-row"><td class="data-label">Obligatory</td><td class="data-value"><p><b>Known exposure:<br />
Must not donate if:</b><br />
Less than six months post the last known contact with the affected individual even if vaccine or intramuscular immunoglobulin was given.</p></td></tr><tr class="data-row"><td class="data-label">Discretionary</td><td class="data-value"><p><b>No known exposure:</b><br />
Accept.</p></td></tr><tr class="data-row"><td class="data-label">See if Relevant</td><td class="data-value"><p><a href="../../../dsg/wb/guidelines/he016-hepatitis-b.html">Hepatitis B - 4. Immunisation</a><br />
<a href="../../../dsg/wb/guidelines/tr005-travel.html">Travel</a></p></td></tr></tbody></table></td></tr><tr class="data-row"><td class="data-label">Additional Information</td><td class="data-value"><p>Hepatitis A is a viral infection of the liver, usually spread by the faecal -oral route or by sewage-contaminated food and water. It is rare in the UK with most cases occurring in people returning from travel to endemic countries. Household contacts of cases are at risk of infection. It can also be spread sexually. Transfusion-transmitted infection is known to occur.<br />
<br />
Hepatitis A usually presents with malaise, fever and abdominal symptoms followed by the onset of jaundice, although some individuals may be asymptomatic. Most people recover after a few weeks but in a small number of cases, infection can lead to more severe liver disease and death. Hepatitis A does not cause long term infection. People who have recovered from hepatitis A have life-long immunity.<br />
<br />
Blood services may screen for hepatitis A infection using a test for hepatitis A virus RNA. Donors who are diagnosed with hepatitis A infection following blood donation screening or as part of an outbreak investigation must be deferred for 6 months, even if they do not have any symptoms of the disease. After 6 months, they can return to donate without further testing.<br />
<br />
Hepatitis A immunisation is often given before travel to parts of the world which also have a risk of infections such as malaria or tropical viruses. The donorâ€™s travel history should be checked if they have had hepatitis A vaccine.<br />
<br />
Hepatitis A immunisation is sometimes given in combination with hepatitis B immunisation. Refer to the Hepatitis B entry if necessary.</p></td></tr><tr class="data-row"><td class="data-label">Reason for change</td><td class="data-value"><p>The entry has been updated to include testing by blood services for hepatitis A virus. The layout has also been reorganised.</p></td></tr><tr class="data-row"><td class="data-label">Donor Information</td><td class="data-value"><p>If you wish to obtain more information regarding a personal medical issue please contact your <a href="../../../dsg/wb/guidelines/nn099-national-help-lines.html">National Help Line</a>.<br />
<br />
Please do not contact this web site for personal medical queries, as we are not in a position to provide individual answers.</p></td></tr></tbody></table>
<div class="pull-right attachments"><div class="cms images">
  
</div></div>

  
<dl class="update-information"><dt class="data-label"><h4>Update Information</h4></dt><dd class="data-value"><p><span class="value">This entry was last updated in:<br />
WB-DSG Edition 203&nbsp;Release 70</span></p></dd></dl>  </td>
</tr>
</table>
</body>
</html>